| Dipeptide derivatives -> Monitor Keywords |
|
|
 
Dipeptide derivativesRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai, Cyclopeptides, 2 Peptide Repeating Units In Known Peptide ChainDipeptide derivatives description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20060058242, Dipeptide derivatives. Brief Patent Description - Full Patent Description - Patent Application Claims
CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of provisional application No. 60/291,088 filed May 15, 2001 and of provisional application No. 60/339,575 filed Dec. 11, 2001, the contents of which are incorporated herein by reference. SUMMARY OF THE INVENTION [0002] The present invention directed to novel vasopeptidase inhibitors described below which are useful as dual inhibitors of both angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP, EC 3.4.24.11). The compounds of the invention are particularly useful for the treatment and/or the prevention of conditions which are responsive to ACE and NEP inhibition, particularly cardiovascular disorders, such as hypertension, isolated systolic hypertension, renal failure (including edema and salt retention), pulmonary edema, left ventricular hypertrophy, heart failure (including congestive heart failure) and atherosclerosis. [0003] The compounds of the invention are also useful for reducing elevated cholesterol plasma levels in mammals. Furthermore, they also inhibit endothelin converting enzyme (ECE) and are useful for the treatment and/or prevention of conditions which are responsive to ECE inhibition. [0004] By virtue of their inhibition of neutral endopeptidase, the compounds of the invention may also be useful for the treatment of pain, depression, certain psychotic conditions, and cognitive disorders. Other potential indications include the treatment of angina, premenstrual syndrome, Meniere's disease, hyperaldosteronism, hypercalciuria, ascites, glaucoma, asthma and gastrointestinal disorders such as diarrhea, irritable bowel syndrome and gastric hyperacidity. [0005] By virtue of their inhibition of ECE, the compounds of the invention may also be useful for the treatment and/or prevention of endothelin dependent conditions and diseases, including cerebral ischemia (stroke), subarachnoid hemorrhage, traumatic brain injury, cerebral vasospasm, arterial hypertrophy, restenosis, Raynaud's disease, myocardial infarction, obesity; also prostate hyperplasia, migraine, diabetes mellitus (diabetic nephropathy), preeclampsia, glaucoma, and transplantaUon rejection such as in aorta or solid organ transplantation; as well as erectile dysfunction. DETAILED DESCRIPTION OF THE INVENTION [0006] The present invention relates to compounds of formula I [0007] wherein [0008] R represents hydrogen, lower alkyl, carbocyclic or heterocyclic aryl-lower alkyl or cycloalkyl-lower alkyl; [0009] R.sub.1 represents lower alkyl, cycloalkyl, carbocyclic or heterocyclic aryl, or biaryl; or R.sub.1 represents (cycloalkyl, carbocyclic aryl, heterocyclic aryl or biaryl)-lower alkyl; [0010] alk represents lower alkylene; [0011] R.sub.3 represents hydrogen or acyl; [0012] R.sub.4 represents hydrogen, optionally substituted lower alkyl, carbocyclic or heterocyclic aryl, (carbocyclic or heterocyclic aryl)-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, biaryl, biaryl-lower alkyl, oxacycloalkyl, thiacycloalkyl, azacycloalkyl, or (oxacycloalkyl, thiacyctoalkyl or azacycloalkyl)-lower alkyl; [0013] R.sub.5 represents hydrogen or lower alkyl; or [0014] R.sub.4 and R.sub.5 together with the carbon atom to which they are attached, represent cycloalkylidene, benzo-fused cycloalkylidene; or 5- or 6-membered (oxacycloalkylidene, thiacycloalkylidene or azacycloalkylidene), each optionally substituted by lower alkyl or aryl-lower alkyl; [0015] R.sub.6 represents lower alkyl, carbocyclic or heterocyclic aryl, (carbocyclic or heterocyclic aryl)-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, biaryl or biaryl-lower alkyl; [0016] R.sub.7 represents lower alkyl, (carbocyclic or heterocyclic aryl)-lower alkyl, cycloalkyl-lower alkyl or biaryl-lower alkyl; or [0017] R.sub.6 and R.sub.7, together with the carbon atom to which they are attached, represent 3- to 10-membered cycloalkylidene which may be substituted by lower alkyl or aryl-lower alkyl or may be fused to a saturated or unsaturated carbocyclic 5- to 7-membered ring; or 5- or 6-membered (oxacycloalkylidene, thiacycloalkylidene or azacycloalkylidene), each optionally substituted by lower alkyl or aryl-lower alkyl; or 2,2-norbonylidene; [0018] X represents --O--, --S(O).sub.n--, --NHSO.sub.2--, or --NHCO--; [0019] n is zero, one or two; and [0020] COOR.sub.2 represents carboxyl or carboxyl derivatized in form of a pharmaceutically acceptable ester; [0021] disulfide derivatives derived from said compounds wherein R.sub.3 is hydrogen; and pharmaceutically acceptable salts thereof. [0022] The present invention is also directed to pharmaceutical compositions comprising said compounds; methods for preparation of said compounds; intermediates; and methods of treating disorders in mammals which are responsive to ACE and NEP inhibition by administration of said compounds to mammals in need of such treatment. [0023] Encompassed by the instant invention are also any prodrug derivatives of compounds of the invention having a free carboxyl, sulfhydryl or hydroxy group, said prodrug derivatives being convertible by solvolysis or under physiological conditions to be the free carboxyl, sulfhydryl and/or hydroxy compounds. Prodrug derivatives are, e.g., the esters of free carboxylic acids and S-acyl and O-acyl derivatives of thiols, alcohols or phenols, wherein acyl has meaning as defined herein. [0024] Pharmaceutically acceptable esters are preferably prodrug ester derivatives, such being convertible by solvolysis or under physiological conditions to the free carboxylic acids of formula I. [0025] Pharmaceutically acceptable prodrug esters are preferably, e.g., lower alkyl esters, aryl-lower alkyl esters, .alpha.-(lower alkanoyloxy)-lower alkyl esters such as the pivaloyloxymethyl ester, and .alpha.-(lower alkoxycarbonyl, morpholinocarbonyl, piperidinocarbonyl, pyrrolidinocarbonyl or di-lower alkylaminocarbonyl)-lower alkyl esters. [0026] Pharmaceutically acceptable salts are salts derived from pharmaceutically acceptable bases for any acidic compounds of the invention, e.g., those wherein COOR.sub.2 represents carboxyl. Such are, e.g., alkali metal salts (e.g., sodium, potassium salts), alkaline earth metal salts (e.g., magnesium, calcium salts) amine salts (e.g., tromeihamine salts). [0027] Compounds of formula I, depending on the nature of substituents, possess two or more asymmetric carbon atoms. The resulting diastereomers and optical antipodes are encompassed by the instant invention. The preferred configuration is indicated in formula Ia. wherein asymmetric carbons carrying the substituents--alk-X--R, and R.sub.4 typically have the S-configuration. [0028] Preferred are the compounds of formula I and Ia wherein R and RS represent hydrogen; R.sub.1 represents lower alkyl, C.sub.5- or C.sub.6-cycloalkyl, carbocyclic or heterocyclic aryl, or (carbocyclic or heterocyclic aryl)-lower alkyl; alk represents lower alkylene; X represents --O-- or --S(O).sub.n wherein n represents zero or two; R.sub.3 represents hydrogen or acyl; R.sub.4 represents optionally substituted lower alkyl, oxacycloalkyl, oxacycloalkyl-lower alkyl, or (carbocyclic or heterocyclic aryl)-lwer alkyl; R.sub.5 represents hydrogen, or R.sub.4 and R.sub.5 combined with the carbon atom to which they are attached represent C.sub.5 or C.sub.6-cycloalkylidene; R.sub.6 and R.sub.7 represent lower alkyl; or R.sub.6 and R.sub.7, together with the carbon atom to which they are attached, represent 5- or 6-membered cycloalkylidene; COOR.sub.2 represents carboxyl or carboxyl derivatized in form of a pharmaceutically acceptable ester; disulfide derivatives derived from said compounds wherein R.sub.3 is hydrogen; and pharmaceutically acceptable salts thereof. [0029] Further preferred are said compounds of formula I and Ia wherein R and R.sub.5 represent hydrogen; R.sub.1 represents carbocyclic or heterocyclic aryl or (carbocyclic or heterocyclic aryl)-lower alkyl; R.sub.3 represents hydrogen or optionally substituted lower alkanoyl; R.sub.4 represents lower alkyl, cycloalkyl, tetrahydropyranyl or C.sub.1-C.sub.4-lower alkoxy-lower alkyl; R.sub.6 and R.sub.7 both represent C.sub.1-C.sub.4-alkyl and are identical; X represents --O-- or --S--; alk represents methylene; COOR.sub.2 represents carboxyl, lower alkoxycarbonyl, (di-lower alkylaminocarbonyl)-lower alkoxycarbonyl or (morpholinbcarbonyl, piperidinocarbonyl or pyrrolidinocarbonyl)-lower alkoxycarbonyl; and pharmaceutically acceptable salts thereof. [0030] Particularly preferred are said compounds of formula I or Ia wherein R and R.sub.5 represent hydrogen; R.sub.1 represents carbocyclic aryl or carbocyclic aryl-lower alkyl in which carbocyclic aryl represents phenyl or phenyl substituted by one or two of hydroxy, lower alkanoyloxy, lower alkyl, lower alkoxy, trifluoromethyl, trifluoromethoxy or halo; R.sub.3 represents hydrogen, lower alkanoyl or lower alkanoyl substituted by lower alkoxy; R.sub.4 represents lower alkyl, 4-tetrahydropyranyl or C.sub.1-C.sub.4-lower alkoxy-C.sub.1-C.sub.4-lower alkyl; R.sub.6 and R.sub.7 represent methyl; X represents --O--; alk represents methylene or ethylene; and COOR.sub.2 represents carboxyl or lower alkoxycarbonyl; and pharmaceutically acceptable salts thereof. An embodiment thereof relates to compounds wherein R.sub.3 represents hydrogen or lower alkanoyl. [0031] Further preferred are the above compounds of formula I or Ia wherein R and R.sub.5 represent hydrogen; R.sub.1 represents phenyl fluorophenyl, benzyl or fluorobenzyl; R.sub.3 represents hydrogen, lower alkanoyl or lower alkanoyl substituted by lower alkoxy; R.sub.4 represents isopropyl, tert-butyl, 1-methoxyethyl or 4-tetrahydropyranyl; R.sub.6 and R.sub.7 represent methyl; X represents --O--; alk represents methylene; and COOR.sub.2 represents carboxyl or lower alkoxycarbonyl; and pharmaceutically acceptable salts thereof. An embodiment thereof relates to compounds wherein R.sub.3 represents hydrogen or lower alkanoyl. [0032] Preferred particular embodiments relate to compounds of formula I or Ia wherein R and R.sub.5 represent hydrogen; R.sub.1 represents benzyl; R.sub.3 represents hydrogen, acetyl or methoxyacetyl; R.sub.4 represents isopropyl or tert-butyl; R.sub.6 and R.sub.7 represent methyl; X represents --O--; alk represents methylene; and COOR.sub.2 represents carboxyl or ethoxycarbonyl; or a pharmaceutically acceptable salt thereof. [0033] The definitions as such or in combination as used herein, unless denoted otherwise, have the following meanings within the scope of the present invention. [0034] Aryl represents carbocyclic or heterocyclic aryl, either monocyclic or bicyclic. [0035] Monocyclic carbocyclic aryl represents optionally substituted phenyl, being preferably phenyl or phenyl substituted by one to three substituents, such being advantageously lower alkyl, hydroxy, lower alkoxy, acyloxy, halogen, cyano, trifluoromethyl, trifluoromethoxy, amino, lower alkanoylamino, lower alkyl-(thio, sulfinyl or sulfonyl), lower alkoxycarbonyl, mono- or di-lower alkylcarbamoyl, or mono- or di-lower alkylamino; or phenyl substituted by lower alkylenedioxy. [0036] Bicyclic carbocyclic-aryl represents 1- or 2-naphthyl or 1- or 2-naphthyl preferably substituted by lower alkyl, lower alkoxy or halogen. Continue reading about Dipeptide derivatives... Full patent description for Dipeptide derivatives Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Dipeptide derivatives patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Dipeptide derivatives or other areas of interest. ### Previous Patent Application: Methods of treating disorders having a component of mercury toxicity Next Patent Application: Methods and compositions for treating diabetes mellitis Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Dipeptide derivatives patent info. IP-related news and info Results in 0.71829 seconds Other interesting Feshpatents.com categories: Software: Finance , AI , Databases , Development , Document , Navigation , Error 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
